Functional changes in OA patients treated with SPMs
Osteoarthritis, OA
OSTEOARTHRITIS
The WOMAC score mean did not significantly differ between patients in the SPMs and the placebo groups at any recorded time (at t = 0: SPMs group: 33.6 ± 19.04, placebo group: 29.6 ± 12.97, p-value = 0.377; at week 4: SPMs group: 24.9 ± 13.71, placebo group: 22.0 ± 10.62, p-value = 0.391; at week 8: SPMs group: 23.1 ± 13.96, placebo group: 23.5 ± 9.97, p-value = 0.921; at week 12: SPMs group: 19.2 ± 12.98, placebo group: 21.3 ± 11.23, p-value = 0.529) (Fig. Functional status of OA patients according to WOMAC (N = 51). Means (standard deviation) are used. Total score derived from the summation of the scores of the answers of the 24 items, which correspond to: none: 0, mild: 1, moderate: 2, severe: 3, and extreme: 4. To compare the WOMAC scores between the SPMs group (N = 23) and placebo group (N = 28), the Mann–Whitney U test (basal) and the Student's t-test (weeks 4, 8, and 12) were used. SPMs: specialized pro-resolving lipid mediators; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index